ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Head and Neck Cancer Targets

Head and Neck Cancer Targets

The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.

A 45-year-old man presents with a mass in the right neck. After the biopsy is performed, what is your diagnosis?

Clinicians now have a new treatment option for patients with recurrent or metastatic head and neck squamous cell carcinoma.

In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.

Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.

Researchers at Boston University School of Medicine have identified a marker that can detect carcinoma-associated fibroblasts (CAFS) in oral cancer tissues.

In this interview, we speak with Dr. Robert Ferris about the results from the CheckMate-141 study, which investigated the efficacy of nivolumab in head and neck cancer.

Pages

Subscribe to Head and Neck Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.